North America Autoinjectors Market

North America Autoinjectors Market Size (2023 to 2028)

The size of the North American Autoinjectors Market is estimated to be worth USD 1.42 billion in 2023 and estimated to be growing at a CAGR of 17.21%, to reach USD 3.16 billion by 2028.

Autoinjectors are the medical devices used to deliver a fixed dose of a particular drug to patients. Most of these autoinjectors are pre-filled spring-loaded syringes, consisting of a hypodermic needle and a push-button to deliver the dose. They are relatively effortless to use and designed to safely administer drugs. In addition, it is technically advanced and has overcome any risks associated with conventional syringes and traditionally used self-injection devices.

There are many varieties of autoinjectors available in the market to meet patients' requirement therapeutic areas. They are mainly intended for the patients' self-medication at home and to reduce needle phobia. Autoinjectors are primarily used to treat anaphylaxis, rheumatoid arthritis, multiple sclerosis, and others. The Autoinjectors market showcases a substantial CAGR during the forecast period with the rising prevalence of an anaphylaxis attack.

The significant factors driving for the North America Autoinjectors Market are technology advancement and innovation in the drug delivery systems, growing adoption of auto-injectors, rising prevalence of anaphylaxis incidences, diabetes, and cancer, simplifying self-medication and improving patient compliance, many advantages like safety, comfort, and the accuracy, favorable government policies and high investments by the private companies.

However, high prices, lack of patient awareness towards self-medication, injuries associated with auto-injectors, and stringent regulations hinder the market growth.

This research report on the North American Autoinjectors market has been segmented & sub-segmented the market into the following categories:

By Product:  

• Fillable Autoinjectors
• Prefilled Autoinjectors

By Usability: 

• Disposable Autoinjectors
• Reusable Autoinjectors

By Manufacturing Design: 

• Standardized Autoinjectors
• Customized Autoinjectors

By Technology: 

• Automated Autoinjectors
• Manual Autoinjectors

By Application: 

• Anaphylaxis
• Multiple Sclerosis
• Rheumatoid Arthritis

By Country: 

• The United States
• Canada
• Rest of North America

Regionally, North America had accounted for the largest share in the global market in 2020. The United States was the major contributor to the North American market due to the rising cases of anaphylaxis, an increase in disposable income, and growth in the pharmaceutical industry. North America dominated the global autoinjectors market, and it is likely to continue its dominance throughout the forecast period. The market growth is attributed to the availability of infrastructure, advanced healthcare technology, and favorable reimbursement policies. 

The United States autoinjectors market is expected to hold a significant market share in the North American market during the forecast period in the regional market. The factors such as the proliferation of chronic and targeted diseases, the rising number of regulatory approvals, and technological advancements in the healthcare sectors are propelling the market growth.  According to Food Allergy Research and Education, approximately 33.1 million Americans suffer from food allergies, including 5.99 million children under 18, or one in 13. The increasing prevalence of anaphylaxis and other types of allergies in the United States leads to faster approvals of new devices by the FDA. An increase in chronic and autoimmune disorders increases the demand for self-administered drugs. On the other hand, as per the centers for disease control and prevention, Arthritis affects 24% of all adults in the United States or 58.5 million individuals, and it is a leading cause of work disability, with an annual cost of $303.5 billion in medical care and lost earnings. Moreover, osteoarthritis is the most frequent type of Arthritis. Arthritis diagnosed by physicians has impaired lifestyle due to arthritis for their daily activities. Patients' increasing prevalence of rheumatoid arthritis and autoinjectors is fuelling the market growth in the North American region.

On the other hand, the Canadian autoinjectors market is also expected to have a considerable market growth rate in terms of revenue due to advanced healthcare infrastructure, increased demand for quality products, and growing investments by the government.

KEY MARKET PLAYERS:

A few of the promising companies operating in the North American Autoinjectors Market profiled in this report are Mylan N.V., Pfizer, Inc., Bayer AG, Becton, Dickinson and Company, Novartis AG, Biogen Idec, Inc., Janssen North America Services, LLC, Sanofi, Unilife Corporation and Eli Lilly and Company.